Physician profile
Samuel E Palmer
NPI 1083663348
$3,544.31
in general payments reported to CMS, 2019-2025
30 companies · $650 in 2025
The $650 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $596 · 2021: $549 · 2022: $496 · 2023: $229 · 2024: $676 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,554.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $934.76 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $347.14 | 2020-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $343.09 | 2019-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $316.83 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $271.13 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Pfizer INC. | $188.56 | 2019-2023 | |
| Astellas Pharma US INC | $171.46 | 2023-2025 | Veozah |
| Jazz Pharmaceuticals INC. | $142.15 | 2019-2020 | |
| Abbvie INC. | $139.98 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $85.26 | 2020-2022 | |
| Dexcom, INC. | $81.34 | 2021-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $61.03 | 2022 | |
| Glaxosmithkline, LLC. | $46.84 | 2021-2024 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $45.21 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $44.66 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $43.77 | 2021 | |
| Merck Sharp & Dohme LLC | $40.46 | 2019-2020 | |
| Medtronic, INC. | $31.41 | 2024 | Minimed 780g |
| Amarin Pharma, INC. | $29.44 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $25.63 | 2019 | |
| Ethicon US, LLC | $20.91 | 2022 | |
| Exact Sciences Corporation | $19.46 | 2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $19.08 | 2025 | Trintellix |
| Ibsa Pharma INC. | $18.88 | 2022 | |
| Currax Pharmaceuticals LLC | $16.00 | 2024 | Contrave |
| Idorsia Pharmaceuticals US INC | $14.85 | 2024 | Quviviq |
| Eisai INC. | $12.64 | 2021 | |
| Xeris Pharmaceuticals, INC. | $12.47 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.87 | 2021 | |
| Phathom Pharmaceuticals, INC. | $8.00 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Palmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.